In conclusion, this analysis of all-cause and cause-specific mortality in a large UK cohort of patients with severe RA has demonstrated that treatment with anti-TNF therapies over a mean of 4 years is not associated with an increased risk of death, as compared with treatment with standard DMARD therapy alone. This evidence concerns the gene TNF and rheumatoid arthritis.